Example: barber
CRESTOR PRESCRIBING INFORMATION
reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C (1.1) ... Monitor INR frequently until stable upon initiation or alteration of CRESTOR therapy. (5.4, 7.6) • Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day)
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Imfinzi Full Prescribing Information
den8dhaj6zs0e.cloudfront.netlung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (1.1) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). (1.2)
Lynparza Prescribing Information
den8dhaj6zs0e.cloudfront.net5.4 Venous Thromboembolic Events 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Use with Anticancer Agents 7.2 Effect of Other Drugs on Lynparza 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.5 Geriatric Use 8.6 Renal Impairment
BREZTRI Full Prescribing Information
den8dhaj6zs0e.cloudfront.netIf the inhaler has not been used for more than 7 days, is dropped, or after weekly . cleaning, prime the inhaler again by releasing 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose counter. BREZTRI AEROSPHERE canister has an attached dose indicator, which indicates . how many inhalations remain.
SYMBICORT Medication Guide
den8dhaj6zs0e.cloudfront.netSYMBICORT comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between SYMBICORT and your other inhaled medications, including the differences in prescribed use and physical appearance.
SYMBICORT Prescribing Information
den8dhaj6zs0e.cloudfront.net5.18 Hypokalemia and Hyperglycemia. 6 ADVERSE REACTIONS. 6.1 Clinical Trials Experience in Asthma 6.2 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease. 6.3 Postmarketing Experience. 7 DRUG INTERACTIONS. Antidepressants 7.3 Beta-Adrenergic Receptor Blocking Agents 7.4 Diuretics. 8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy …
US-56427 ---------------------------- DOSAGE AND ...
den8dhaj6zs0e.cloudfront.netnot start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG). (5.1, 6.1) • If: possible, manage bleeding without discontinuing ----- BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events. (5.4) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS IN PATIENTS WITH ACS ...
Farxiga Prescribing Information
den8dhaj6zs0e.cloudfront.netpatients with polycystic kidney disease or patients requiring or with a recent . history of immunosuppressive therapy for the treatment of kidney disease. FARXIGA is not expected to be effective in these populations. (1)----- DOSAGE AND ADMINISTRATION ----- • Assess volume status and correct volume depletion before initiating. ...
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE ...
den8dhaj6zs0e.cloudfront.netHealthcare Providers for detail on preparation and administration. (2) ... registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives).
Saphnelo full Prescribing Information
den8dhaj6zs0e.cloudfront.netwith severe active lupus nephritis or severe active central nervous system lupus. Use . of SAPHNELO is not recommended in these situations. (1)----- DOSAGE AND ADMINISTRATION -----The recommended dosage is 300 mg as an intravenous infusion over a 30-minute . …
CALQUENCE PRESCRIBING INFORMATION
den8dhaj6zs0e.cloudfront.netTable 1: Recommended Dose Modifications for Use with CYP3A Inhibitors or Inducers CYP3A Co-administered Drug Recommended CALQUENCE use Inhibition Strong CYP3A inhibitor Avoid concomitant use. If these inhibitors will be used short-term (such as anti-infectives for up to seven days), interrupt CALQUENCE. Moderate CYP3A inhibitor 100 mg once daily.
Related documents
Guidelines for the management of an elevated INR on ...
protocols.sonichealthcare.comINR 4.5-10 and no bleeding Cease warfarin therapy; consider reasons for elevated INR and patient-specific factors. Vitamin K 1 is usually unnecessary If bleeding risk is high*: • consider Vitamin K 1 1-2 mg orally or 0.5-1 mg IV • measure INR within 24 h • resume warfarin at a reduced dose once INR approaches therapeutic range INR > 10 ...
BRIDGING ANTICOAGULATION PROTOCOL FOR …
seslhd.health.nsw.gov.auTest INR on the day before surgery, where appropriate and feasible, to identify patients with elevated INRs and permit timely use of corrective oral vitamin K thereby avoiding blood product administration or surgery deferral Assess postoperative hemostasis, preferably on the day of surgery and on the first ...
PT, INR, and APTT Testing
www.doh.wa.govThe INR result is the patient's PT result in seconds divided by the geometric mean of the PT result of the laboratory's normal patients, as calculated by each laboratory. ... acute phase reactants that are elevated in times of stress, and inflammation can …
ELEVATED LIVER ENZYMES
web.brrh.comWorkup for Elevated Serum Aminotransferase Levels •History and physical exam •Discontinue all hepatotoxic medications and EtOH •Assess for risk factors for fatty liver and viral hepatitis •Routine labs: CBC, CMP, PT/INR •Additional labs: “Rules of 3” •Imaging: Liver ultrasound with Doppler, Fibroscan, CT/MRI, MRCP, ERCP
Lab Test Interpretation Table - BC Cancer
www.bccancer.bc.caInternational Normalized Ratio (INR) PT may be reported as a standardized INR value or 0.8 – 1.2 seconds (normal) (aPTT) Partial Thromboplastin Time (PTT) 60 – 70 seconds Activated Partial Thromboplastin Time (aPTT) 30 - 40 seconds be The liver is responsible for synthesizing a number of different clotting factors. Unlike albumin, PT offers a
PRESCRIBING INFORMATION ARGATROBAN
www.accessdata.fda.gov(INR W), based on INR for co-therapy of warfarin and Argatroban (INR WA), when the Argatroban dose is 2 mcg/kg/min, use the equation next to the appropriate curve. Example: At a dose of 2 mcg/kg/min and an INR performed with Thromboplastin A, the equation 0.19 + 0.57 (INR WA) = INR W would allow a prediction of the INR on warfarin alone (INR W
Recommended Therapeutic Range for Warfarin Therapy
www.mnhospitals.org*Consider long-term low-intensity (INR 1.5-2.0) or standard intensity (INR 2-3) warfarin therapy for patients with idiopathic events. Adapted from Haines ST. Recommended Therapeutic Range for Warfarin Therapy – ASHP Anticoagulation Service Traineeship 2002. Page 3.